Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

Inclusion Criteria:

• Healthy child

• Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant

• Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 yearsprior to challenge dose

Exclusion Criteria:

• Receipt of more than 3 doses of any Hepatitis B containing vaccine

• History of clinical diagnosis of infection due to Hepatitis B

• History or current close contact with known carriers of Hepatitis B virus

• Prior known sensitivity or allergy to any component of HBVAXPRO

• Chronic illness / medical condition that could interfere with study conduct orcompletion

• Coagulation disorder that would contraindicate intramuscular injection

• Subject is pregnant

• Receipt of corticosteroids for more than 14 days in the 30 days prior to study

• Receipt of Immunoglobulins, blood or blood-derived products in the 3 months prior tostudy

• Planned participation in another clinical study